Skip to main content
Premium Trial:

Request an Annual Quote

Evogene Closes US IPO, Raising $84.8M

NEW YORK (GenomeWeb News) – Evogene today announced the closing of its US initial public offering, raising $84.8 million in gross proceeds.

The Israel-based plant genomics firm went public in the US last week. It said today that underwriters on the offering exercised their option in full to purchase up to 750,000 additional shares at $14.75 per share, the same price as in its public offering. Credit Suisse Securities and Deutsche Bank Securities were joint book-running managers, while Oppenheimer and Piper Jaffray were co-managers on the offering.

The company, which also trades on the Tel Aviv Stock Exchange, filed to go public in the US in September, saying at the time that it intended to offer $60 million of its shares.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.